Seroepidemiology and clinical features of hepatitis delta among <scp>HBsAg</scp> carriers: a study from Hepatitis Clinic of Iranian Blood Transfusion Organization

Keshvari, Maryam; Alavian, Seyed Moayed; Aghaee, Bahareh Lashtoo; Behnava, Bita; Mahdavi, Meisam; Fesharaki, Mohammad Gholami; Sharafi, Heidar

doi:10.1111/tme.12163

Cited by 12 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Coinfection of Hepatitis D virus (HDV) with Hepatitis B virus (HBV) increases the risk of progression to end-stage liver diseases such as cirrhosis and hepatocellular carcinoma (HCC) (1,2). The prevalence of HDV infection in individuals with HBsAg varies by their clinical presentations of the disease (more prevalent in cirrhotic than in noncirrhotic patients) and geographical location (high prevalence in South America, Eastern Europe, and Sub-Saharan Africa and low prevalence in Western Europe, North America, and Southeast Asia) (3,4). Pegylated-interferon with 20% -30% treatment success is the currently available standard of care for the management of HDV infection (5).…”

Section: Contextmentioning

confidence: 99%

Global Distribution of Hepatitis D Virus Genotypes: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Context: Hepatitis D virus (HDV) infection, as the main coinfection in patients with chronic hepatitis B, leads to progressive liver disease. Elucidating the global distribution of HDV genotypes may be beneficial for the development of HDV vaccines and antiviral agents. Objectives: Through this systematic review, we aimed to present a clear picture of HDV genotype dispersal at the global and regional levels. Methods: A systematic search was performed in Scopus, PubMed, and Web of Science using the relevant keywords of hepatitis D and HDV genotype. The old HDV genotype classification (HDV I, II, and III) and African HDV genotypes (HDV-5,-6,-7, and-8) were used for showing the HDV genetic dispersion. The data of the country-level distribution of HDV genotypes were translated to the regional and global distributions of HDV genotypes. Results: Among all 1,318 unique titles, 71 studies were screened in the qualitative synthesis consisting of 77 records from 33 countries (sampling locations). In Africa, the most common genotype was HDV I, followed by African HDV genotypes. In Asia, the most frequent genotype was HDV II, followed by HDV I. In Europe and Oceania, the most common HDV genotype was HDV I, followed by HDV II and African genotypes. In the Middle East and North America, the most frequent HDV genotype was HDV I. In South America, the most common HDV genotype was HDV III, followed by HDV I and African genotypes. Conclusions: We found HDV I is distributed globally. Other HDV genotypes are observed regionally: HDV II mainly in East Asia, HDV III exclusively in South America, and African genotypes mainly in West Africa. PROSPERO #: CRD42018097296.

show abstract

Section: Contextmentioning

confidence: 99%

Global Distribution of Hepatitis D Virus Genotypes: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Likewise, the prevalence rates of the infection in Turkey (9.6%) and Iraq (6.6%) were higher than the prevalence reported in the present study (23,24). Furthermore, an earlier study demonstrated a significantly higher HDV seroprevalence (26.66%) among Afghans who immigrated to Iran than among Iranian patients (1.85%) (25).…”

Section: Discussionmentioning

confidence: 88%

Sero-Prevalence of Hepatitis D Virus Infection Among Hepatitis B Surface Antigen Positive Patients in Mashhad, Northeastern Iran

et al. 2019

View full text Add to dashboard Cite

Background: Transmission and persistence of Hepatitis Delta Virus (HDV) depends on presence of the hepatitis B surface antigen (HBsAg) envelope proteins. The prevalence of HDV infection has not been reported previously among HBsAg-positive patients in Mashhad, Iran. Objectives: To evaluate HDV seroprevalence among individuals with HBsAg seropositivity in Mashhad, Northeastern Iran. Methods: This cross-sectional was performed in Central Diagnostic Lab of Academic Center for Education, Culture, and Research (ACECR), Mashhad, Iran. Based on database of the lab, 606 HBsAg positive patients were tested for anti-HDV antibodies using the enzyme-linked immunosorbent assay (ELISA) during 2016-2017. Chi-square or Fisher's exact tests and T-test were used to analyze the data by SPSS software at a significance level of 5%. Results: Among 606 HBsAg positive patients including 335 (55.3%) males and 271 (44.7%) females with a mean age of 43.6 ± 14.8 years old, 35 cases (5.8%) were found to be anti-HDV positive. HDV infection was more prevalent among males (6.9%), older patients (P = 0.008), and individuals with elevated ALT (P = 0.034) and AST serum levels (P = 0.021). Regarding HBV viral load, there was no significant difference between HBV/HDV co-infected and HBV mono-infected patients (P = 0.07). Conclusions: Prevalence of HDV infection was found to be relatively high among HBsAg-positive cases in this region. Therefore, it is suggested to assess HDV antibodies among HBsAg-positive patients, especially those with higher serum levels of transaminases.

show abstract

Section: To the Editormentioning

confidence: 99%

“…HDV has a worldwide distribution; the infection is endemic in the Middle East, Mediterranean countries, Central Africa, and northern parts of South America (2). Clinical outcomes vary from asymptomatic to fulminant hepatitis; although, HDV is usually related to a severe form of hepatitis (2). HDV has no specific functional enzyme to be targeted for therapy, therefore, using Interferon (IFN)-based treatments are the only available treatment for a chronic HDV infection with low efficacy around 10% -40% (3,4).…”

Section: To the Editormentioning

confidence: 99%

Polymorphisms of IFNL3 and Response to Interferon-Based Treatments in Patients with Hepatitis D Infection: Systematic Review and Meta-Analysis

Sharafi

Amirahmadi

Alavian

2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

The hepatitis D virus (HDV) is a RNA virus that needs the hepatitis B virus (HBV) surface antigen (HBsAg) to complete its life cycle (1). HDV has a worldwide distribution; the infection is endemic in the Middle East, Mediterranean countries, Central Africa, and northern parts of South America (2). Clinical outcomes vary from asymptomatic to fulminant hepatitis; although, HDV is usually related to a severe form of hepatitis (2). HDV has no specific functional enzyme to be targeted for therapy, therefore, using Interferon (IFN)-based treatments are the only available treatment for a chronic HDV infection with low efficacy around 10% -40% (3, 4). Previously, it was found that polymorphisms near IFNL3 (IL28B) modify the rate of response to IFN-based treatments in patients with the hepatitis C infection (5). It is of great interest to observe whether the same is true in patients with the HDV infection who were treated with IFN-based treatments (6-10). This short systematic review and meta-analysis aimed to evaluate the impact of polymorphisms near IFNL3 (rs12979860 and rs8099917) on sustained virologic response (SVR) in patients with the HDV infection who were treated with IFNbased treatments.In this study, we searched PubMed, Scopus, and Web of Science for the relevant articles with the following keywords: "HDV", "Hepatitis D", "IL28B", and "IFNL3" (Search date: 25 August, 2016). The search results were screened for appropriate titles and abstracts. Finally, full-texts were evaluated for inclusion of the studies in the meta-analysis. The Peto method was used for pooling the data. Data analysis was performed using Review Manager 5.3 (Cochrane Collaboration, London, UK).The systematic search identified 42 articles while finally, 5 articles were included after exclusion of duplicates and screening of titles, abstracts, and full-texts. The data of the included studies are presented in Table 1. All of the 5 included studies assessed the rs12979860 polymorphism, including a total of 246 patients with the HDV infection who were treated with IFN-based treatments. Based on the forest plot in Figure 1A, the rate of SVR to IFN-based treatments was slightly lower in HDV patients with rs12979860 CC than in those with rs12979860 non-CC genotypes (26.4% vs. 37.5%) (P = 0.05; OR = 0.57; 95%CI = 0.33-1.01). Moreover, 3 studies including a total of 96 patients with the HDV infection were available with the data of impact of rs8099917 polymorphism on SVR rate to IFN-based treatments. As shown in Figure 1B, the SVR rate was not significantly different between HDV patients with rs8099917 TT and non-TT genotypes treated with IFN-based treatments (40.7% vs. 45.9%) (P = 0.75; OR = 0.87; 95%CI = 0.38 -2.03).While the studies on patients with HCV infection showed that rs12979860 CC genotype is associated with a favorable response to IFN-based treatment (5), the current meta-analysis showed that rs12979860 CC might be associated with a lower response rate to IFN-based treatments in patients with HDV infection than those with rs12979860 non-CC...

show abstract

Seroepidemiology and clinical features of hepatitis delta among HBsAg carriers: a study from Hepatitis Clinic of Iranian Blood Transfusion Organization

Abstract: The seroprevalence of HDV in HBsAg-positive individuals in this study was about 2% which seems to be lower than the global prevalence of HDV.

Cited by 12 publications

References 37 publications

Global Distribution of Hepatitis D Virus Genotypes: A Systematic Review

Global Distribution of Hepatitis D Virus Genotypes: A Systematic Review

Sero-Prevalence of Hepatitis D Virus Infection Among Hepatitis B Surface Antigen Positive Patients in Mashhad, Northeastern Iran

Polymorphisms of IFNL3 and Response to Interferon-Based Treatments in Patients with Hepatitis D Infection: Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About